Daratumumab (PBS)

For research use only. Not for therapeutic Use.

  • CAT Number: I040744
  • CAS Number: 945721-28-8
  • Purity: ≥95%
Inquiry Now

Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition[1][2].
Daratumumab (Anti-Human CD38) induces potent Ab-dependent cellular cytotoxicity in CD38-expressing lymphoma- and MM-derived cell lines[2].
Daratumumab (i.p.; 0.5 mg/kg; 14 d after challenge with Daudi-luc cells) inhibits outgrowth of CD38-expressing tumor cells in mouse xenograft tumor models[2].


Catalog Number I040744
CAS Number 945721-28-8
Purity ≥95%
Reference

[1]. Ghose J, Viola D, et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018;7(10):e1486948. Published 2018 Jul 23.
 [Content Brief]

[2]. de Weers M, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-1848.
 [Content Brief]

Request a Quote